Edition:
United States

Merrimack Pharmaceuticals Inc (MACK.OQ)

MACK.OQ on NASDAQ Stock Exchange Global Market

5.27USD
17 Aug 2018
Change (% chg)

$0.15 (+2.93%)
Prev Close
$5.12
Open
$5.14
Day's High
$5.31
Day's Low
$5.11
Volume
12,570
Avg. Vol
51,558
52-wk High
$15.38
52-wk Low
$4.74

Chart for

About

Merrimack Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in designing novel treatments for cancer by targeting biomarker-defined cancers. Its clinical programs include MM-121 (seribantumab), MM-141 (istiratumab) and MM-310. MM-121 is a fully human monoclonal antibody that binds to the... (more)

Overall

Beta: 2.09
Market Cap(Mil.): $70.32
Shares Outstanding(Mil.): 13.34
Dividend: 10.55
Yield (%): --

Financials

  MACK.OQ Industry Sector
P/E (TTM): -- 99.36 30.45
EPS (TTM): -2.46 -- --
ROI: -29.81 2.89 12.63
ROE: -38.91 1.65 14.82

Merrimack to scrap development of pancreatic cancer treatment

Merrimack Pharmaceuticals Inc said on Monday it would stop developing its experimental treatment for pancreatic cancer after it failed to meet the main and secondary goals in a mid-stage trial.

Jun 25 2018

UPDATE 1-Merrimack to scrap development of pancreatic cancer treatment

June 25 Merrimack Pharmaceuticals Inc said on Monday it would stop developing its experimental treatment for pancreatic cancer after it failed to meet the main and secondary goals in a mid-stage trial.

Jun 25 2018

Merrimack to scrap development of pancreatic cancer treatment

June 25 Merrimack Pharmaceuticals Inc said on Monday it would discontinue the development of an experimental treatment for pancreatic cancer after the drug failed to meet the main and secondary goals of a mid-stage trial.

Jun 25 2018

BRIEF-Merrimack Pharmaceuticals Reports Q1 Operating Loss Per Share Of $1.33

* THREE CLINICAL READOUTS EXPECTED IN 2018, INCLUDING DATA FROM TWO RANDOMIZED PHASE 2 STUDIES

May 08 2018

BRIEF-Merrimack Provides Business Update And Reports 2017 Financial Results

* MERRIMACK PROVIDES BUSINESS UPDATE AND REPORTS 2017 FINANCIAL RESULTS

Mar 12 2018

BRIEF-Merrimack Strengthens SHERLOC Study Of MM-121 In Non-Small Cell Lung Cancer

* MERRIMACK STRENGTHENS SHERLOC STUDY OF MM-121 IN NON-SMALL CELL LUNG CANCER

Mar 12 2018

BRIEF-Merrimack Says Dosed First Patient In Randomized Phase 2 Clinical Study Of MM-121

* MERRIMACK - ‍ DOSED FIRST PATIENT IN RANDOMIZED PHASE 2 CLINICAL STUDY OF MM-121 IN PATIENTS WITH POST-MENOPAUSAL METASTATIC BREAST CANCER​

Feb 26 2018

Competitors

Earnings vs. Estimates